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A B S T R A C T
Three extractable Bacillus anthracis cell-wall-associated antigens were evaluated for potential use as skin
testing agents, and as possible candidates for in-vitro diagnosis of anthrax immunity. Anthraxin and a
partially purified extractable antigen (EAP) were produced from avirulent B. anthracis strain 34F2
(Sterne). The thermoextractable antigen used for the Ascoli reaction was obtained commercially. Guinea-
pigs were immunised and boosted several times subcutaneously with the Sterne live veterinary anthrax
vaccine. Four weeks after the last booster dose, animals were skin-tested with the three antigens. Serum
antibody levels were also determined by ELISA, and the in-vitro T-cell response was evaluated by [3H]-
thymidine incorporation. EAP was the most active antigen in both the serological and cellular reactions.
EAP also elicited a distinct positive skin reaction in animals immunised with B. anthracis. The data
obtained in this preliminary study indicated that extractable cell-wall antigens obtained from the
vegetative form of B. anthracis may be used for skin tests and in-vitro testing of specific humoral and cell-
mediated anthrax immunity.
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I N T R O D U C T I O N
Anthrax has recently re-emerged as a potential
biological weapon. Following a hypothetical
attack in which a large population is exposed to
aerosolised Bacillus anthracis, certain individuals
will have been exposed to the pathogen in various
doses, while others may be unexposed or protec-
ted. Yet treatment for the entire population at risk
is identical, consisting of antibiotic therapy for
60 days and repeated anthrax vaccinations [1,2].
Long-term antibiotic therapy may be associated
with increased costs, risk of adverse events, and the
development of antibiotic resistance in B. anthracis
and commensals. Currently, the shortage of
anthrax vaccine does not allow the duration of
antibiotic treatment or prophylaxis to be reduced.
As a result, it might be important to differentiate
between individuals who have been exposed to
B. anthracis, and therefore need a full vaccination
schedule and prolonged antibiotic therapy or post-
exposure prophylaxis, and those who have not
been exposed. Since antibiotics kill B. anthracis
rapidly, diagnostic tests that are based on a micro-
biological detection of the organism may not be
relevant in a population that has been treated with
antibiotics, even for a very short duration [3].
The anthraxin skin test, which measures cell-
mediated immunity to anthrax antigens, has been
used as a diagnostic tool in the former USSR and
in Russia [3–6]. Skin testing has also been recom-
mended by the World Health Organisation for
evaluation of the immunological memory against
anthrax in humans and animals [7]. Skin test
screening can be applied successfully with anti-
gens extracted from the anthrax bacillus cell-wall,
but not by using the protective antigen, which is
the major antigen of the anthrax vaccine used in
the USA and western Europe [8]. Therefore, the
anthraxin skin test can differentiate between
exposed and unexposed individuals, even if they
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have been immunised. However, as it is a skin
test, an individual may become sensitised follow-
ing repeated testing, and a false-positive reaction
may occur. An in-vitro test of cell-mediated and
humoral immune responses might circumvent
this problem.
In the present study, three different extractable
B. anthracis antigens were evaluated for potential
use as skin test agents, and for the in-vitro
detection of cell-mediated and humoral immunity
in guinea-pigs immunised with the Sterne live
veterinary anthrax vaccine; these were a partially
purified extractable antigen, anthraxin, and a
thermoextractable antigen used for the Ascoli
reaction.
M A T E R I A L S A N D M E T H O D S
The avirulent B. anthracis strain 34F2 (Sterne) was obtained
from the Onderstepoort Bioproduct Institute (Onderstepoort,
South Africa). Thermoextractable antigen (ATE; Bioveta, Iva-
novice na Hane´, Czech Republic) was used as the routine
positive control for the Ascoli reaction. The concentration of
the protein in ATE was determined as 14.28 mg ⁄L.
Anthraxin preparation
The Sterne strain was grown for 18–20 h at 37 C on Brain Heart
Infusion agar (Oxoid, Basingstoke, UK), supplemented with
yeast extract. Before harvesting, the culture was tested for
homogeneity and purity, i.e., microscopically there were c. 80%
vegetative cell filaments and 20% bacillus forms, with few
spores present. The bacterial mass was washed twice with
phosphate buffered saline pH 7.3 (PBS), and centrifuged at
800 g for 30 min. The pellet was autoclaved for 30 min at
120 C, dispensed into sterile dishes and dried at room
temperature. The dried pellet was triturated in a sterile mortar
and de-fatted with ether and chloroform in a Soxsclet appar-
atus. The resulting powder was hydrolysed by mixing 1 g with
100 mL of acetic acid 1% v ⁄v. The suspension was boiled at
100C for 3 h with periodic shaking, cooled to room tempera-
ture and placed at 4C overnight. The supernatant was
centrifuged twice at 3000 g and cleared by filtration through a
paper filter type 595 (Schleicher and Schull, Keene, NH, USA),
repeated until a clear yellowish liquid was obtained. The filtrate
was adjusted to pH 7.4 with NaOH 10% w ⁄v, and the protein
concentration was determined with a BCA protein kit (Pierce
Biotechnology, Rockford, IL, USA). The immunochemical
specificity of the product obtained was evaluated by the
Ouchterlony test, using a monospecific anthrax-precipitating
immune serum (Bioveta) to yield one line of precipitation after
overnight incubation. The anthraxin preparation was dispensed
in vials, autoclaved for 30 min at 120C and stored at 4–8 C.
Preparation of extractable antigenic protein (EAP)
Intact B. anthracis Sterne strain cells (10 g) were suspended
in 80 mL of buffer containing 0.1 M Tris-HCl pH 8.0, 5 mM
EDTA, 5 mM iodacetamide, and 5 mM amino-caproic acid,
vortexed at 4C for 2 h, and centrifuged at 3500 g for
15 min. This was repeated three times. The final cell pellet
was suspended in 20 mL of 0.1 M Tris-HCl pH 8.0 contain-
ing N-lauryl sarcosine (ICN Pharmaceuticals, Costa Mesa,
CA, USA) 3% w ⁄v and extracted as described above. The
supernatants were pooled and dialysed overnight at 4 C
against double-distilled water. At 4 C, 12 mL of sepharose
CL-4B (Amersham, Uppsala, Sweden) was added to 60 mL
of the supernatant, while stirring. Ammonium sulphate was
added to achieve 70% saturation and the mixture stirred on
ice for 1 h. The sepharose was collected and the mixture put
on a sintered glass filter and washed under vacuum with
0.5 L saturated (70% w ⁄v) ammonium sulphate solution,
prepared in 5 mM K2HPO4 pH 6.8. The combined eluate,
containing EAP, was dialysed overnight at 6 C against 30
volumes of 5 mM K2HPO4–KH2PO4 pH 8.0 containing 5 mM
EDTA, 5 mM iodacetamide, and 5 mM amino-caproic acid.
The partially purified EAP (15.7 mL) was loaded on to a
hydroxylapatite column equilibrated with 5 mM K2HPO4–
KH2PO4 pH 6.8 at 6 C. Under these conditions, EAP bound
to the column, which was then washed with the same
buffer. EAP was eluted as a single peak with a non-linear
3.3 column volume gradient (0.078–1 M K2HPO4 – KH2PO4
pH 5.7). The collected fractions were analysed by
SDS–PAGE. Fractions (98 kDa) containing pure EAP were
pooled and dialysed against double-distilled water over-
night. The protein concentration was determined with the
BCA protein assay reagent, after which the preparation was
lyophilised. The serological activity and purity of the EAP
were evaluated by the Ouchterlony test, using precipitating
sera for the Ascoli reaction (Bioveta; Omsk Biofactory,
Omsk, Russia; State Veterinary Institute, Bucharest, Roma-
nia) to give a single precipitating line. These sera were
prepared from different animals (donkeys, horses, mules),
immunised with a variety of virulent and attenuated
B. anthracis strains.
Immunisation of guinea-pigs
Ten white male guinea-pigs (250–300 g) were kept in quaran-
tine for 1 week before subcutaneous immunisation with the
Sterne live anthrax veterinary vaccine (Colorado Serum Com-
pany, Denver, CO, USA) containing 5.6 · 106 spores ⁄mL. The
schedule was 2 · 106 spores on day zero, 4 · 106 spores on day
15, and 5.6 · 106 spores on day 30. Ten non-immunised male
guinea-pigs were used as controls.
Skin testing of guinea-pigs
On day 28 after the last B. anthracis booster dose, nine
vaccinated and five control animals were tested with anthraxin,
EAP and ATE. Intradermal injections (0.1 mL) were spaced
2–4 cm apart on both sides of the previously epilated skin of the
trunk. Reading of the skin reactions was performed after 24 h.
Erythema and skin infiltration, if present at the site of injection,
were graded 1–4. Briefly, grade 0 was a negative skin reaction
(no erythema, no induration), and grade 0.5 was assigned to
erythema without induration. Grade 1 was skin erythema with
a diameter of 8–15 mm accompanied by induration, and grade
4 was given to a reaction with an erythema of > 40 mm with
accompanying induration [3]. Immediately after the skin test
reading, all guinea-pigs were bled by cardiac puncture and the
sera were separated by centrifugation.
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Antibody determination by ELISA
The wells of MaxiSorp microtitre plates (Nunc, Roskilde,
Denmark) were coated with 100 lL of the corresponding
antigen (5 mg ⁄L in 50 mM bicarbonate buffer pH 9.5) for 16 h
at 4 C. The plates were washed three times with PBS
containing Tween-20 0.05% v ⁄v (PBST), and were blocked
with 200 lL bovine serum albumin 3% w ⁄v in PBS (PBS-BSA)
for 2 h at room temperature. After three additional washes,
100 lL of serum, diluted 1 : 100 in PBS-BSA, was added and
incubated for 2 h at room temperature. After washing, 100 lL
of affinity-purified alkaline phosphatase-conjugated, goat anti-
guinea-pig IgG antibodies (Jackson Immuno-Research Labor-
atory, West-Growe, PA, USA) diluted 1:10 000 in PBS-BSA
were added and plates were incubated for 1 h at room
temperature. After five washes with PBS-BSA, the plates were
developed with 1000 mg ⁄L p-nitrophenylphosphate (Sigma, St
Louis, MO, USA) and the absorbance was determined at
405 nm.
T-cell response to the antigens
Single cell suspensions were prepared from the spleens of five
immunised and five control animals by meshing on a 100-lm
nylon filter, followed by a series of washings with RPMI-1640
medium supplemented with syngeneic serum 1% v ⁄v. Red
blood cells were lysed with 0.15 M NH4Cl, 1 mM KHCO3,
0.1 mM Na2EDTA pH 7.3. Aliquots of 3 · 105 cells in RPMI
containing penicillin 100 000 U ⁄L, streptomycin 10 mg ⁄L,
2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essen-
tial amino acids, 5 · 10)5 M 2-mercaptoethanol, and syngeneic
serum 1% v ⁄v, were plated into each well of 96-well flat-
bottomed plates (Nunc) in the presence of the following
stimuli: concavalin A (Con-A 1.5 mg ⁄L; Sigma), EAP, anthr-
axin and ATE (5, 2.5, and 1.25 mg ⁄L, respectively). Each
stimulation was performed in triplicate. Plates were incubated
for 72 h at 37C in CO2 5% v ⁄v. For the last 12 h, cultures were
pulsed with 1 lCi of [3H]-thymidine. The cells were harvested
on to glass-fibre filters (Brandel, Gaithersburg, MD, USA) and
the [3H]-thymidine incorporation into DNA was measured by
a b-counter (Packard 1600 TR; Hewlett Packard, Palo Alto, CA,
USA). Results, in counts per minute (cpm) were expressed as
an index of stimulation (IS) where IS ¼ (cpm with antigen –
cpm without antigen) ‚ cpm without antigen.
R E S U L T S
Anthraxin and ATE preparations (20 lg ⁄ guinea-
pig) elicited similar results in immunised ani-
mals, whilst the average reaction grade was
lower for EAP (Table 1). The skin test results of
non-immunised animals were negative for all
three antigens.
Levels of IgG to all three antigens were raised
significantly in the sera of immunised animals.
The highest levels were observed with EAP
(Table 2). The results for five tested and five
non-tested animals in the control group were
combined, as there were no differences in anti-
body levels to the antigens (p > 0.05).
T-cell immune response in immunised animals
revealed a significant proliferation of splenocytes
after stimulation with EAP (Table 3).
D I S C U S S I O N
Anthraxin, a cell-wall extract from the vegetative,
non-capsulated Sterne strain of B. anthracis, con-
sists mainly of a complex of peptidoglycans and
polysaccharides [9]. Immunological analysis of
animals immunised with the Sterne veterinary
vaccine revealed that the antibodies elicited
recognise a cell-associated extractable antigen,
characterised as a major S-layer protein of the
vegetative Sterne strain [10]. Therefore, this anti-
gen, EAP, was included in the present study.
EAP proved to be the most active antigen.
Firstly, EAP produced positive skin test reactions
in guinea-pigs vaccinated with a live anthrax
vaccine. Consequently, EAP can be used to
evaluate cellular immunity in vivo, similar to the
conventional anthraxin test. Secondly, EAP was
used as an ELISA antigen for the determination of
antibodies in the sera of animals vaccinated with
live anthrax vaccine. Thirdly, use of EAP identi-
fied a lymphocyte proliferation response from
immunised animal cells, allowing it to be used in
an in-vitro test evaluating cell-mediated immu-
nity to anthrax.
The two other antigens demonstrated compar-
able results in skin tests and satisfactory serological
Table 1. Graded reactions after skin tests with Bacillus
anthracis antigens in guinea-pigs immunised with the
Sterne veterinary vaccine
Anthrax
antigens
Number of tested
guinea-pigs
Total points
positivea
Mean
value
Anthraxin 9 16 1.8
ATE 9 18 2.0
EAP 6b 8 1.3
aSkin reactions were graded on a scale of 0–5.
bThe antigen produced was sufficient to test six animals only.
ATE, themoextractable antigen; EAP, extractable antigenic protein.
Table 2. IgG antibody levels in sera of immunised and
control guinea-pigs measured by ELISA using different
Bacillus anthracis antigens
Antigen Immunised (n = 10) Control (n = 10) p value
EAP 1.441 ± 0.122 0.370 ± 0.07 p < 0.001
Anthraxin 0.569 ± 0.154 0.265 ± 0.03 p < 0.01
ATE 1.124 ± 0.121 0.351 ± 0.06 p < 0.001
ATE, themoextractable antigen; EAP, extractable antigenic protein.
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activity in ELISA, but were not active in the
lymphocyte proliferation assay.
Cellular and humoral reactions following expo-
sure to these three envelope antigens would arise
only after contact with the vegetative form of
B. anthracis, or following vaccination with the
whole bacterium. These reactions would not be
expected to be positive in individuals immunised
against anthrax with the protective antigen
vaccine unless these individuals had also been
exposed to the anthrax microorganism. In addi-
tion, these reactions would be expected to be
positive in non-immunised individuals who had
been exposed to B. anthracis. Thus, these antigens
could be used to differentiate between individuals
who have not been immunised but have been
exposed, and those individuals who have been
immunised and either exposed or not exposed to
the organism. Such differentiation could prevent
unnecessary antibiotic therapy and reserve anti-
biotic prophylaxis for anthrax-exposed individu-
als.
In conclusion, data obtained in this preliminary
study indicated that extractable antigens from the
cell wall of the vegetative B. anthracis organism
can be used to evaluate cell-mediated immunity
with in-vivo skin tests, and to test for specific
humoral and T-cell-mediated immunity in vitro.
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Table 3. Splenocyte proliferation
after stimulation of guinea-pigs with
different Bacillus anthracis antigensAntigen
concentration
(mg ⁄mL)
Index of stimulation (mean ± sd)a
EAP ATE Anthraxin
Immunised Control Immunised Control Immunised Control
1.25 4.32 ± 1.23 0.87 ± 0.27 1.77 ± 0.29 1.13 ± 0.18 1.69 ± 0.14 0.9 ± 0.075
2.5 6.21 ± 0.98 1.28 ± 0.36 1.75 ± 0.33 1.24 ± 0.14 1.82 ± 0.12 1.1 ± 0.09
0.5 6.13 ± 0.9 1.32 ± 0.7 1.84 ± 0.56 1.37 ± 0.11 1.78 ± 0.1 0.93 ± 0.06
aFive animals were tested in each group.
ATE, themoextractable antigen; EAP, extractable antigenic protein.
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